Nangibotide in patients with septic shock: a Phase 2a randomized controlled clinical trial - François, Bruno; Wittebole, Xavier; Ferrer, Ricard; Mira, Jean-Paul; Dugernier, Thierry; Gibot, Sébastien; Derive, Marc; Olivier, Aurélie; Cuvier, Valérie; Witte, Stephan; Pickkers, Peter; Vandenhende, François; et al. (Intensive care medicine, 2020)
Keywords: Anesthesiology; Animal models; Animals; Antibodies; Biological products; Biomarkers; Clinical trials; Critical Care Medicine; Double-Blind Method; Drug dosages; Emergency Medicine; Health aspects; Humans; Immunologic Factors; Intensive; Intensive care; Medicine; Medicine & Public Health; Original; Pain Medicine; Patients; Pediatrics; Pharmacodynamics; Pharmacokinetics; Pharmacology; Pneumology/Respiratory System; Randomization; Safety; Sepsis; Septic shock; Shock, Septic - drug therapy; Treatment Outcome; Belgium; France; Canada; TREM-1; Septic shock; LR12; Nangibotide